WAVE Life Sciences Ltd (WVE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 71.28 is considered Overvalued compared with the five-year average of -5.19. The fair price of WAVE Life Sciences Ltd (WVE) is between 10.04 to 13.70 according to relative valuation method. Compared to the current price of 13.85 USD , WAVE Life Sciences Ltd By Overvalued By 1.07%.

Relative Value

Fair Zone

10.04-13.70

Current Price：13.85

1.07%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is WAVE Life Sciences Ltd (WVE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

WAVE Life Sciences Ltd (WVE) has a current Price-to-Book (P/B) ratio of 20.53. Compared to its 3-year average P/B ratio of -28.24, the current P/B ratio is approximately -172.69% higher. Relative to its 5-year average P/B ratio of -130.76, the current P/B ratio is about -115.70% higher. WAVE Life Sciences Ltd (WVE) has a Forward Free Cash Flow (FCF) yield of approximately -6.79%. Compared to its 3-year average FCF yield of -10.75%, the current FCF yield is approximately -36.87% lower. Relative to its 5-year average FCF yield of -24.73%, the current FCF yield is about -72.55% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for WVE competitors is 213.46, providing a benchmark for relative valuation. WAVE Life Sciences Ltd Corp (WVE.O) exhibits a P/S ratio of 71.28, which is -66.61% above the industry average. Given its robust revenue growth of -79.41%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of WVE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of WVE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is WVE currently overvalued or undervalued?

What is WAVE Life Sciences Ltd (WVE) fair value?

WVE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of WAVE Life Sciences Ltd (WVE) is between 10.04 to 13.70 according to relative valuation method.

How does WVE's valuation metrics compare to the industry average?

The average P/S ratio for WVE's competitors is 213.46, providing a benchmark for relative valuation. WAVE Life Sciences Ltd Corp (WVE) exhibits a P/S ratio of 71.28, which is -66.61% above the industry average. Given its robust revenue growth of -79.41%, this premium appears unsustainable.

What is the current P/B ratio for WAVE Life Sciences Ltd (WVE) as of Mar 03 2026?

As of Mar 03 2026, WAVE Life Sciences Ltd (WVE) has a P/B ratio of 20.53. This indicates that the market values WVE at 20.53 times its book value.

What is the current FCF Yield for WAVE Life Sciences Ltd (WVE) as of Mar 03 2026?

As of Mar 03 2026, WAVE Life Sciences Ltd (WVE) has a FCF Yield of -6.79%. This means that for every dollar of WAVE Life Sciences Ltd's market capitalization, the company generates -6.79 cents in free cash flow.

What is the current Forward P/E ratio for WAVE Life Sciences Ltd (WVE) as of Mar 03 2026?

As of Mar 03 2026, WAVE Life Sciences Ltd (WVE) has a Forward P/E ratio of -13.08. This means the market is willing to pay $-13.08 for every dollar of WAVE Life Sciences Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for WAVE Life Sciences Ltd (WVE) as of Mar 03 2026?

As of Mar 03 2026, WAVE Life Sciences Ltd (WVE) has a Forward P/S ratio of 71.28. This means the market is valuing WVE at $71.28 for every dollar of expected revenue over the next 12 months.

WVE Valuation